Top experts press HHS on Alzheimer's drug registries; a conflict of interest behind Apellis eye drug warning

Taking stock of the drug industry, from the lab to the medicine chest

July 27, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Molly Ferguson/STAT STAT+ | A conflict of interest behind the warning on Apellis' eye drug? The optics are not good The physician in charge of a committee that flagged a rare but severe side effect involving the Apellis drug has ties to a rival drugmaker. By Adam Feuerstein STAT+ | Policy experts call on Medicare to ensure data from Alzheimer's drug registries is shared publicly Experts argue that Medicare coverage should not be provided for any registry that fails to appropriately share population-level patient data. By Ed Silverman and Rachel Cohrs Biogen's sticky situation, Wegovy's risks, & biotech insider trading This episode, we discuss why Wall Street was less than convinced by Biogen's attempt to assuage concerns about its credibility. By Damian Garde and Meg Tirrell and Adam Feuerstein Susan Walsh/AP Biden announces an advanced cancer research initiative as part of the bipartisan 'moonshot' effort The initiative aims to help doctors more easily distinguish between cancer cells and healthy tissue during surgery and improve outcomes. By Associated Press

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser